abstract: Circulating levels of plasma @entity0 -17 beta, @entity6 , @entity5 , @entity4 , immunoreactive insulin, plasma @entity3 , and protein were measured at interval during the period of final gonadal maturation, prior to spawning of male and female @entity7 . Plasma @entity0 levels fluctuated significantly and generally covaried in males and females through time. In females, possibly in relation to environmental changes, mean plasma @entity0 levels peaked four times during the final spawning period but decreased sharply at the time of ovulation. In males, mean plasma @entity0 peaked seven times during the final prespawning period and, in contrast to females, peaked significantly at the time of final spermiation. Plasma @entity6 were extremely low and covaried in males and females through time. Like plasma @entity1 profiles, there were coordinated changes in plasma @entity4 and @entity5 levels in males and females through the prespawning season. There was a slight increase in plasma insulin during the terminal maturation of the lampreys. However, at ovulation, the insulin levels abruptly decreased in females, whereas in males they remained unchanged. Plasma protein and @entity2 levels gradually decreased until ovulation/spermiation. At ovulation plasma @entity2 levels increased.

title: Changes in plasma @entity1 and thyroid hormones and insulin during final maturation and spawning of the XXXX , @entity7 .

answer: @entity7


abstract: Circulating levels of plasma @entity0 -17 beta, @entity6 , @entity5 , @entity4 , immunoreactive insulin, plasma @entity3 , and protein were measured at interval during the period of final gonadal maturation, prior to spawning of male and female @entity7 . Plasma @entity0 levels fluctuated significantly and generally covaried in males and females through time. In females, possibly in relation to environmental changes, mean plasma @entity0 levels peaked four times during the final spawning period but decreased sharply at the time of ovulation. In males, mean plasma @entity0 peaked seven times during the final prespawning period and, in contrast to females, peaked significantly at the time of final spermiation. Plasma @entity6 were extremely low and covaried in males and females through time. Like plasma @entity1 profiles, there were coordinated changes in plasma @entity4 and @entity5 levels in males and females through the prespawning season. There was a slight increase in plasma insulin during the terminal maturation of the lampreys. However, at ovulation, the insulin levels abruptly decreased in females, whereas in males they remained unchanged. Plasma protein and @entity2 levels gradually decreased until ovulation/spermiation. At ovulation plasma @entity2 levels increased.

title: Changes in plasma @entity1 and thyroid hormones and insulin during final maturation and spawning of the @entity7 , XXXX .

answer: @entity7


abstract: We compared the effectiveness and incidence of nephrotoxicity of @entity4 - @entity7 and @entity8 in 73 cirrhotics who had severe @entity6 . Most of these @entity0 had @entity3 . @entity0 were randomly allocated into two groups. Group I included 36 @entity0 treated with @entity4 - @entity7 and Group II comprised 37 @entity0 treated with @entity8 . @entity0 from both groups were similar with respect to clinical data, standard liver and renal function tests, types of @entity2 and isolated organisms. Ninety-two per cent of bacteria isolated in Group I and 98% of those isolated in Group II were susceptible in vitro to @entity4 - @entity7 and to @entity8 , respectively. @entity4 - @entity7 cured the @entity2 in 56% of Group I @entity0 , and @entity8 in 85% of Group II @entity0 (p less than 0.02). Five @entity0 treated with @entity4 - @entity7 , and none treated with @entity8 developed superinfections (p = 0.024). Nephrotoxicity ( @entity1 associated with an increase of urinary @entity5 to over 2,000 micrograms per liter) occurred in two @entity0 in Group I and none in Group II. These results suggest that broad-spectrum cephalosporins should be considered as first choice antibiotics in cirrhotic @entity0 with severe @entity2 .

title: XXXX is more effective than is @entity4 - @entity7 in cirrhotics with severe @entity2 .

answer: @entity8


abstract: We compared the effectiveness and incidence of nephrotoxicity of @entity4 - @entity7 and @entity8 in 73 cirrhotics who had severe @entity6 . Most of these @entity0 had @entity3 . @entity0 were randomly allocated into two groups. Group I included 36 @entity0 treated with @entity4 - @entity7 and Group II comprised 37 @entity0 treated with @entity8 . @entity0 from both groups were similar with respect to clinical data, standard liver and renal function tests, types of @entity2 and isolated organisms. Ninety-two per cent of bacteria isolated in Group I and 98% of those isolated in Group II were susceptible in vitro to @entity4 - @entity7 and to @entity8 , respectively. @entity4 - @entity7 cured the @entity2 in 56% of Group I @entity0 , and @entity8 in 85% of Group II @entity0 (p less than 0.02). Five @entity0 treated with @entity4 - @entity7 , and none treated with @entity8 developed superinfections (p = 0.024). Nephrotoxicity ( @entity1 associated with an increase of urinary @entity5 to over 2,000 micrograms per liter) occurred in two @entity0 in Group I and none in Group II. These results suggest that broad-spectrum cephalosporins should be considered as first choice antibiotics in cirrhotic @entity0 with severe @entity2 .

title: @entity8 is more effective than is @entity4 - XXXX in cirrhotics with severe @entity2 .

answer: @entity7


abstract: We compared the effectiveness and incidence of nephrotoxicity of @entity4 - @entity7 and @entity8 in 73 cirrhotics who had severe @entity6 . Most of these @entity0 had @entity3 . @entity0 were randomly allocated into two groups. Group I included 36 @entity0 treated with @entity4 - @entity7 and Group II comprised 37 @entity0 treated with @entity8 . @entity0 from both groups were similar with respect to clinical data, standard liver and renal function tests, types of @entity2 and isolated organisms. Ninety-two per cent of bacteria isolated in Group I and 98% of those isolated in Group II were susceptible in vitro to @entity4 - @entity7 and to @entity8 , respectively. @entity4 - @entity7 cured the @entity2 in 56% of Group I @entity0 , and @entity8 in 85% of Group II @entity0 (p less than 0.02). Five @entity0 treated with @entity4 - @entity7 , and none treated with @entity8 developed superinfections (p = 0.024). Nephrotoxicity ( @entity1 associated with an increase of urinary @entity5 to over 2,000 micrograms per liter) occurred in two @entity0 in Group I and none in Group II. These results suggest that broad-spectrum cephalosporins should be considered as first choice antibiotics in cirrhotic @entity0 with severe @entity2 .

title: @entity8 is more effective than is XXXX - @entity7 in cirrhotics with severe @entity2 .

answer: @entity4


abstract: We compared the effectiveness and incidence of nephrotoxicity of @entity4 - @entity7 and @entity8 in 73 cirrhotics who had severe @entity6 . Most of these @entity0 had @entity3 . @entity0 were randomly allocated into two groups. Group I included 36 @entity0 treated with @entity4 - @entity7 and Group II comprised 37 @entity0 treated with @entity8 . @entity0 from both groups were similar with respect to clinical data, standard liver and renal function tests, types of @entity2 and isolated organisms. Ninety-two per cent of bacteria isolated in Group I and 98% of those isolated in Group II were susceptible in vitro to @entity4 - @entity7 and to @entity8 , respectively. @entity4 - @entity7 cured the @entity2 in 56% of Group I @entity0 , and @entity8 in 85% of Group II @entity0 (p less than 0.02). Five @entity0 treated with @entity4 - @entity7 , and none treated with @entity8 developed superinfections (p = 0.024). Nephrotoxicity ( @entity1 associated with an increase of urinary @entity5 to over 2,000 micrograms per liter) occurred in two @entity0 in Group I and none in Group II. These results suggest that broad-spectrum cephalosporins should be considered as first choice antibiotics in cirrhotic @entity0 with severe @entity2 .

title: @entity8 is more effective than is @entity4 - @entity7 in cirrhotics with severe XXXX .

answer: @entity2


abstract: UNASSIGNED: @entity11 ( @entity11 ) syndrome is a rare disease of unknown etiology defined by the combination of @entity6 , @entity5 , and biochemical abnormalities. It has been reported that @entity11 mainly affects adolescents and young @entity0 . Here we reported a special case regarding a 60-year-old @entity0 with @entity2 due to @entity11 documented by renal biopsy.We present a rare case of an elderly @entity0 , who had been suffering from a fever for 2 weeks, characterized by sudden onset and resolving spontaneously, and accompanied by extreme fatigue, @entity4 , and shivering. Renal biopsy showed a @entity6 , with polymorphonuclear infiltration and acute @entity10 . In the outpatient clinic, he was diagnosed with idiopathic bilateral anterior @entity5 1 month ago. Ophthalmological examination revealed anterior asymptomatic @entity5 . Human @entity9 *0101/0201 and @entity7 *0303/0503) was found which supported the suspect of @entity11 . The @entity0 was treated with oral @entity1 (1mg/kg) and continued for 8 weeks on tapering doses. Serum @entity3 normalized within 3 and 6 months later renal function also recovered completely.This case highlights that @entity11 is probably an underdiagnosed disease responsible for some cases of @entity8 in elderly male @entity0 . It is of critical importance to be aware of this syndrome by nephrologist and ophthalmologists in this special population. Further studies are needed to elucidate clinical characteristic and pathogenesis of @entity11 in elderly population.

title: @entity6 and XXXX Syndrome in an Elderly @entity0 : Case Report and Literature Review.

answer: @entity5


abstract: UNASSIGNED: @entity11 ( @entity11 ) syndrome is a rare disease of unknown etiology defined by the combination of @entity6 , @entity5 , and biochemical abnormalities. It has been reported that @entity11 mainly affects adolescents and young @entity0 . Here we reported a special case regarding a 60-year-old @entity0 with @entity2 due to @entity11 documented by renal biopsy.We present a rare case of an elderly @entity0 , who had been suffering from a fever for 2 weeks, characterized by sudden onset and resolving spontaneously, and accompanied by extreme fatigue, @entity4 , and shivering. Renal biopsy showed a @entity6 , with polymorphonuclear infiltration and acute @entity10 . In the outpatient clinic, he was diagnosed with idiopathic bilateral anterior @entity5 1 month ago. Ophthalmological examination revealed anterior asymptomatic @entity5 . Human @entity9 *0101/0201 and @entity7 *0303/0503) was found which supported the suspect of @entity11 . The @entity0 was treated with oral @entity1 (1mg/kg) and continued for 8 weeks on tapering doses. Serum @entity3 normalized within 3 and 6 months later renal function also recovered completely.This case highlights that @entity11 is probably an underdiagnosed disease responsible for some cases of @entity8 in elderly male @entity0 . It is of critical importance to be aware of this syndrome by nephrologist and ophthalmologists in this special population. Further studies are needed to elucidate clinical characteristic and pathogenesis of @entity11 in elderly population.

title: XXXX and @entity5 Syndrome in an Elderly @entity0 : Case Report and Literature Review.

answer: @entity6


abstract: UNASSIGNED: @entity11 ( @entity11 ) syndrome is a rare disease of unknown etiology defined by the combination of @entity6 , @entity5 , and biochemical abnormalities. It has been reported that @entity11 mainly affects adolescents and young @entity0 . Here we reported a special case regarding a 60-year-old @entity0 with @entity2 due to @entity11 documented by renal biopsy.We present a rare case of an elderly @entity0 , who had been suffering from a fever for 2 weeks, characterized by sudden onset and resolving spontaneously, and accompanied by extreme fatigue, @entity4 , and shivering. Renal biopsy showed a @entity6 , with polymorphonuclear infiltration and acute @entity10 . In the outpatient clinic, he was diagnosed with idiopathic bilateral anterior @entity5 1 month ago. Ophthalmological examination revealed anterior asymptomatic @entity5 . Human @entity9 *0101/0201 and @entity7 *0303/0503) was found which supported the suspect of @entity11 . The @entity0 was treated with oral @entity1 (1mg/kg) and continued for 8 weeks on tapering doses. Serum @entity3 normalized within 3 and 6 months later renal function also recovered completely.This case highlights that @entity11 is probably an underdiagnosed disease responsible for some cases of @entity8 in elderly male @entity0 . It is of critical importance to be aware of this syndrome by nephrologist and ophthalmologists in this special population. Further studies are needed to elucidate clinical characteristic and pathogenesis of @entity11 in elderly population.

title: @entity6 and @entity5 Syndrome in an Elderly XXXX : Case Report and Literature Review.

answer: @entity0


abstract: STUDY DESIGN: A retrospective case study. OBJECTIVE: To confirm the remodeling potential of the kyphotic @entity3 in the pediatric spine. SUMMARY OF BACKGROUND DATA: Nonsurgical reduction and immobilization is the gold standard for the @entity2 in infancy. However, the reduction occasionally results in incomplete repositioning of the odontoid process. The cervical spine is subsequently immobilized until fusion in most cases in the hope of achieving remodeling with the growth of the remaining displacement and kyphotic angulation, although there are no precise data on the acceptable limit of the deformity. METHODS: Three @entity0 (age at injury = 1 year 2 months to 3 years) with odontoid process @entity2 in infancy were treated conservatively and the @entity2 were observed on plain lateral radiographs until at least the age of 20 years. For evaluation of the angulated odontoid process, we used our original measurement method of the odontoid process tilting angle (OPTA). In addition, the OPTAs were also measured in 127 Japanese adult @entity0 (57 male @entity0 and 70 female @entity0 ; average age = 43 years) without a history of @entity2 , as normal controls. RESULTS: The OPTA in the normal controls was -21.4      23.3  . The OPTAs ranged from 41   to 62   at the initial evaluation, from 12   to 30   at the time of bony union, and from -4   to -14   at the final follow-up at more than 20 years of age, which were all within one standard deviation of the mean in the normal adult controls. CONCLUSION: @entity2 with the OPTA around 30   at the time of bony union in @entity0 younger than 3 years of age could have the capacity for remodeling to the normal morphology. No surgical reduction might be needed to recommend complete apposition of the odontoid process in the absence of severe or deteriorating @entity1 .

title: Remodeling capacity of XXXX in kyphotic angulation in infancy: an observation up to maturity in three @entity0 .

answer: @entity3


abstract: STUDY DESIGN: A retrospective case study. OBJECTIVE: To confirm the remodeling potential of the kyphotic @entity3 in the pediatric spine. SUMMARY OF BACKGROUND DATA: Nonsurgical reduction and immobilization is the gold standard for the @entity2 in infancy. However, the reduction occasionally results in incomplete repositioning of the odontoid process. The cervical spine is subsequently immobilized until fusion in most cases in the hope of achieving remodeling with the growth of the remaining displacement and kyphotic angulation, although there are no precise data on the acceptable limit of the deformity. METHODS: Three @entity0 (age at injury = 1 year 2 months to 3 years) with odontoid process @entity2 in infancy were treated conservatively and the @entity2 were observed on plain lateral radiographs until at least the age of 20 years. For evaluation of the angulated odontoid process, we used our original measurement method of the odontoid process tilting angle (OPTA). In addition, the OPTAs were also measured in 127 Japanese adult @entity0 (57 male @entity0 and 70 female @entity0 ; average age = 43 years) without a history of @entity2 , as normal controls. RESULTS: The OPTA in the normal controls was -21.4      23.3  . The OPTAs ranged from 41   to 62   at the initial evaluation, from 12   to 30   at the time of bony union, and from -4   to -14   at the final follow-up at more than 20 years of age, which were all within one standard deviation of the mean in the normal adult controls. CONCLUSION: @entity2 with the OPTA around 30   at the time of bony union in @entity0 younger than 3 years of age could have the capacity for remodeling to the normal morphology. No surgical reduction might be needed to recommend complete apposition of the odontoid process in the absence of severe or deteriorating @entity1 .

title: Remodeling capacity of @entity3 in kyphotic angulation in infancy: an observation up to maturity in three XXXX .

answer: @entity0


abstract: The expression of @entity6 and @entity5 was studied in 10 benign cartilage-forming @entity1 (5 osteochondromas and 5 chondromas) and 39 @entity2 (14 central, 4 periosteal, 7 dedifferentiated, and 14 secondary @entity1 ). No expression of MMP and @entity5 was detected in benign cartilage-forming @entity1 . In @entity2 , the expression of @entity6 was detected in 84.6%, of @entity3 in 71.8, of @entity4 in 97.4, and of @entity5 in 82.4% cases, the levels of expression of these markers varied from 10 to 60%. The expression of @entity6 was not associated with @entity0 gender, maximum size and degree of differentiation of the @entity1 , but was linked with age. The expression of @entity6 was more often detected in central and dedifferentiated @entity2 ; the expression of @entity6 (+) was significantly associated with 3-year relapse-free and 5-year overall survival of the @entity0 . The expression of @entity6 in the @entity1 was associated with unfavorable course of the disease. The values of @entity3 expression in @entity2 did not reflect the main clinical morphological characteristics of the disease and its prognosis. The level of @entity4 protein expression in @entity2 >= 40% is prognostically unfavorable, while <40% is a favorable factor for 3-year relapse-free survival. The risk of disease relapse within 1 year after the beginning of therapy was maximum in T3 @entity1 with expression of @entity4 protein >= 40%. No relationships between the parameters of @entity5 expression in @entity2 and the main clinical morphological characteristics of the disease and its prognosis were detected.

title: Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitor-1 in cartilage-forming XXXX .

answer: @entity1


abstract: BACKGROUND: This study examines whether quality of life measured with non-disease specific instruments is altered by @entity2 surgery and whether the effect is modulated by the presence of @entity5 or other non-ocular issues. METHODS: Thirteen @entity0 were assessed pre- and at three months post- @entity2 surgery. @entity1 was measured with the Visual Disability Assessment. Quality of life was measured using two established generic instruments: the Cantril Ladder and the Profile of Mood States (POMS). Subjects were also asked to report any events that may have influenced their quality of life in the three months after surgery. RESULTS: Visual acuity and @entity1 were significantly improved by surgery (p < 0.01). Cantril Ladder score was significantly improved after surgery (p = 0.04). The POMS score improved significantly after surgery, only when cases with @entity5 were excluded (p = 0.04). Two cases had a large deterioration in POMS score that was attributable in one case, to the death of a partner and in the other (a @entity0 with severe @entity4 ) to @entity3 from the realisation that there was no further potential for visual improvement. DISCUSSION: Quality of life can be measurably improved by @entity2 surgery. However, this is less likely if @entity5 is present. The use of generic instruments for outcome studies increases the likely influence of external factors on quality of life measures. Disease specific instruments, such as the Visual Disability Assessment, should be used wherever possible in outcomes research.

title: XXXX surgery and changes in quality of life measures.

answer: @entity2


abstract: @entity2 are highly lethal @entity1 resistant to current therapies. The standard treatment modality for these @entity1 , surgical resection followed by radiation therapy and concurrent @entity6 , has demonstrated activity, but development of resistance and disease progression is common. Although oncogenic Ras mutations are uncommon in @entity2 , Ras has been found to be constitutively activated through the action of upstream signaling pathways, suggesting that farnesyltransferase inhibitors may show activity against these @entity1 . We now report the in vitro and orthotopic in vivo results of combination therapy using radiation, @entity6 and @entity9 ( @entity9 ), an oral @entity8 transferase inhibitor, in a @entity3 model of @entity5 . We examined the viability, proliferation, farnesylation of @entity7 , and activation of downstream signaling of combination-treated U87 cells in vitro. @entity9 alone or in combination with radiation and @entity6 had limited @entity1 cell @entity4 in vitro although it did demonstrate significant inhibition in @entity1 cell proliferation. In vivo, @entity9 alone had a modest ability to inhibit orthotopic U87 @entity1 , radiation and @entity6 demonstrated better inhibition, while significant anti- @entity1 activity was found with concurrent @entity9 , radiation, and @entity6 , with the majority of animals demonstrating a decrease in @entity1 volume. The use of @entity1 neurospheres derived from freshly resected adult @entity0 @entity5 tissue was relatively resistant to both @entity6 and radiation therapy. @entity9 had a significant inhibitory activity against these neurospheres and could potentate the activity of @entity6 and radiation. These data support the continued research of high grade @entity2 treatment combinations of @entity8 transferase inhibitors, @entity6 , and radiation therapy.

title: @entity9 ( @entity9 ) improves the activity of XXXX and radiation for orthotopic @entity2 .

answer: @entity6


abstract: @entity2 are highly lethal @entity1 resistant to current therapies. The standard treatment modality for these @entity1 , surgical resection followed by radiation therapy and concurrent @entity6 , has demonstrated activity, but development of resistance and disease progression is common. Although oncogenic Ras mutations are uncommon in @entity2 , Ras has been found to be constitutively activated through the action of upstream signaling pathways, suggesting that farnesyltransferase inhibitors may show activity against these @entity1 . We now report the in vitro and orthotopic in vivo results of combination therapy using radiation, @entity6 and @entity9 ( @entity9 ), an oral @entity8 transferase inhibitor, in a @entity3 model of @entity5 . We examined the viability, proliferation, farnesylation of @entity7 , and activation of downstream signaling of combination-treated U87 cells in vitro. @entity9 alone or in combination with radiation and @entity6 had limited @entity1 cell @entity4 in vitro although it did demonstrate significant inhibition in @entity1 cell proliferation. In vivo, @entity9 alone had a modest ability to inhibit orthotopic U87 @entity1 , radiation and @entity6 demonstrated better inhibition, while significant anti- @entity1 activity was found with concurrent @entity9 , radiation, and @entity6 , with the majority of animals demonstrating a decrease in @entity1 volume. The use of @entity1 neurospheres derived from freshly resected adult @entity0 @entity5 tissue was relatively resistant to both @entity6 and radiation therapy. @entity9 had a significant inhibitory activity against these neurospheres and could potentate the activity of @entity6 and radiation. These data support the continued research of high grade @entity2 treatment combinations of @entity8 transferase inhibitors, @entity6 , and radiation therapy.

title: @entity9 ( @entity9 ) improves the activity of @entity6 and radiation for orthotopic XXXX .

answer: @entity2


abstract: @entity2 are highly lethal @entity1 resistant to current therapies. The standard treatment modality for these @entity1 , surgical resection followed by radiation therapy and concurrent @entity6 , has demonstrated activity, but development of resistance and disease progression is common. Although oncogenic Ras mutations are uncommon in @entity2 , Ras has been found to be constitutively activated through the action of upstream signaling pathways, suggesting that farnesyltransferase inhibitors may show activity against these @entity1 . We now report the in vitro and orthotopic in vivo results of combination therapy using radiation, @entity6 and @entity9 ( @entity9 ), an oral @entity8 transferase inhibitor, in a @entity3 model of @entity5 . We examined the viability, proliferation, farnesylation of @entity7 , and activation of downstream signaling of combination-treated U87 cells in vitro. @entity9 alone or in combination with radiation and @entity6 had limited @entity1 cell @entity4 in vitro although it did demonstrate significant inhibition in @entity1 cell proliferation. In vivo, @entity9 alone had a modest ability to inhibit orthotopic U87 @entity1 , radiation and @entity6 demonstrated better inhibition, while significant anti- @entity1 activity was found with concurrent @entity9 , radiation, and @entity6 , with the majority of animals demonstrating a decrease in @entity1 volume. The use of @entity1 neurospheres derived from freshly resected adult @entity0 @entity5 tissue was relatively resistant to both @entity6 and radiation therapy. @entity9 had a significant inhibitory activity against these neurospheres and could potentate the activity of @entity6 and radiation. These data support the continued research of high grade @entity2 treatment combinations of @entity8 transferase inhibitors, @entity6 , and radiation therapy.

title: XXXX ( @entity9 ) improves the activity of @entity6 and radiation for orthotopic @entity2 .

answer: @entity9


abstract: @entity2 are highly lethal @entity1 resistant to current therapies. The standard treatment modality for these @entity1 , surgical resection followed by radiation therapy and concurrent @entity6 , has demonstrated activity, but development of resistance and disease progression is common. Although oncogenic Ras mutations are uncommon in @entity2 , Ras has been found to be constitutively activated through the action of upstream signaling pathways, suggesting that farnesyltransferase inhibitors may show activity against these @entity1 . We now report the in vitro and orthotopic in vivo results of combination therapy using radiation, @entity6 and @entity9 ( @entity9 ), an oral @entity8 transferase inhibitor, in a @entity3 model of @entity5 . We examined the viability, proliferation, farnesylation of @entity7 , and activation of downstream signaling of combination-treated U87 cells in vitro. @entity9 alone or in combination with radiation and @entity6 had limited @entity1 cell @entity4 in vitro although it did demonstrate significant inhibition in @entity1 cell proliferation. In vivo, @entity9 alone had a modest ability to inhibit orthotopic U87 @entity1 , radiation and @entity6 demonstrated better inhibition, while significant anti- @entity1 activity was found with concurrent @entity9 , radiation, and @entity6 , with the majority of animals demonstrating a decrease in @entity1 volume. The use of @entity1 neurospheres derived from freshly resected adult @entity0 @entity5 tissue was relatively resistant to both @entity6 and radiation therapy. @entity9 had a significant inhibitory activity against these neurospheres and could potentate the activity of @entity6 and radiation. These data support the continued research of high grade @entity2 treatment combinations of @entity8 transferase inhibitors, @entity6 , and radiation therapy.

title: @entity9 ( XXXX ) improves the activity of @entity6 and radiation for orthotopic @entity2 .

answer: @entity9


abstract: Diagnostic tests for @entity2 ( @entity2 ) involving @entity5 blockade of cholinergic oculomotor functions were examined in @entity2 @entity0 (n=15), @entity1 ( @entity1 ) @entity0 (n=15), and non-clinical control (NC) @entity0 (n=15). Pupillographic methods were used to measure pupil diameter and pupillary light reflexes after double-blind ocular administration of dilute @entity5 (0.01%) in one eye and saline in the other eye. Changes in pupil size were measured in bright background light and near-darkness. @entity5 increased pupil diameter to a similar extent in all three groups in light and darkness. @entity5 also reduced the amplitude and latency of the pupillary light reflex to a similar extent for all three groups. @entity5 pupillary response tests, therefore, were not sensitive or specific diagnostic tests for @entity2 . Peak constriction amplitude of the pupillary light reflex was significantly reduced in both eyes in @entity2 and @entity1 groups relative to non-clinical controls, but @entity2 and @entity1 groups did not differ significantly. The pupillary light reflex test, therefore, was sensitive to @entity2 , but lacked adequate specificity. Finally, peak constriction amplitude correlated significantly with @entity3 severity and @entity4 treatment may have partially normalized pupillary light reflex abnormalities in @entity2 @entity0 . The pupillary light reflex test, therefore, may index central cholinergic dysfunction associated with disease progression and improvement in cholinergic function associated with pharmacologic treatment response in @entity2 .

title: XXXX effects on pupil size and pupillary light reflexes in @entity1 .

answer: @entity5


abstract: Diagnostic tests for @entity2 ( @entity2 ) involving @entity5 blockade of cholinergic oculomotor functions were examined in @entity2 @entity0 (n=15), @entity1 ( @entity1 ) @entity0 (n=15), and non-clinical control (NC) @entity0 (n=15). Pupillographic methods were used to measure pupil diameter and pupillary light reflexes after double-blind ocular administration of dilute @entity5 (0.01%) in one eye and saline in the other eye. Changes in pupil size were measured in bright background light and near-darkness. @entity5 increased pupil diameter to a similar extent in all three groups in light and darkness. @entity5 also reduced the amplitude and latency of the pupillary light reflex to a similar extent for all three groups. @entity5 pupillary response tests, therefore, were not sensitive or specific diagnostic tests for @entity2 . Peak constriction amplitude of the pupillary light reflex was significantly reduced in both eyes in @entity2 and @entity1 groups relative to non-clinical controls, but @entity2 and @entity1 groups did not differ significantly. The pupillary light reflex test, therefore, was sensitive to @entity2 , but lacked adequate specificity. Finally, peak constriction amplitude correlated significantly with @entity3 severity and @entity4 treatment may have partially normalized pupillary light reflex abnormalities in @entity2 @entity0 . The pupillary light reflex test, therefore, may index central cholinergic dysfunction associated with disease progression and improvement in cholinergic function associated with pharmacologic treatment response in @entity2 .

title: @entity5 effects on pupil size and pupillary light reflexes in XXXX .

answer: @entity1


abstract: BACKGROUND: Particle radiotherapy is a novel treatment for @entity1 . The present study aimed to evaluate risk factors for overall survival and local control after particle radiotherapy of @entity2 ( @entity2 ), and to identify suitable candidates for this treatment. METHODS: All @entity0 with a single @entity2 smaller than 5 cm in diameter treated by particle radiotherapy between 2001 and 2008 were identified retrospectively from a prospectively collected database. Clinical outcomes and prognostic factors were analysed. RESULTS: A total of 150 @entity0 were included. Five-year overall survival and local control rates were 50.9 and 92.3 per cent respectively. Multivariable analysis revealed that several factors, including age and @entity0 -Pugh classification, significantly influenced overall survival. Proximity to the digestive tract and @entity0 -Pugh classification were independent risk factors for local recurrence. Other @entity1 factors including size, gross classification, previous treatment, macroscopic vascular invasion, and @entity1 location in relation to the diaphragm and large vessels did not influence local control rate. CONCLUSION: Particle radiotherapy seems safe and effective, and may be a novel treatment for small @entity2 . Recurrences are more frequent when the @entity1 is located close to the gut.

title: Risk factors for survival and local recurrence after particle radiotherapy for XXXX .

answer: @entity2


abstract: BACKGROUND: Histopathological subtyping of @entity5 ( @entity5 ) is currently relevant in treatment decision because of a differential activity of specific therapeutic agents. Immunohistochemistry highlights cell differentiation lineages and, in this study, it was applied to maximize the proportion of accurately subtyped @entity5 @entity6 ( @entity6 ) on fine-needle aspiration cytology (FNAC) samples. METHODS: Cell blocks from 103 FNAC samples with a morphological diagnosis of @entity5 were immunostained for cytokeratin (CK) 7, @entity7 , @entity10 , and @entity8 , whereas @entity8 , napsin A (Naps-A), and @entity11 ( @entity11 ) were only assessed in a subgroup of cases with discordant ( @entity9 and @entity10 + for nonsquamous, @entity7 and @entity8 + for squamous) findings. Results were correlated with surgical specimens evaluated by morphology alone. RESULTS: Thirty-seven (36%) @entity1 with @entity9 / @entity10 + and @entity7 / @entity8 - corresponded to 35 cases of @entity3 ( @entity3 ) and 2 cases of @entity2 , whereas 9 (9%) cases with the reverse immunoprofile were @entity4 ( @entity4 ) at surgery (P < .001). Although the remaining 57 cases had different marker combinations, a correlation was found with @entity3 histology for @entity10 + samples (independent of other markers) and with @entity4 for @entity8 +/ @entity10 - immunophenotype (P < .001). @entity8 was never expressed in @entity8 + @entity3 , whereas Naps-A was restricted to @entity3 and @entity11 to @entity4 lineage. The percentage of unclassified @entity5 decreased from 36% to 14%. Combinations of 2 antibodies ( @entity10 / @entity11 or @entity8 /Naps-A) in the same section allowed diagnostic optimization in scant cytological samples. CONCLUSIONS: [corrected] This 4-antibody panel approach may contribute to refine @entity0 classification in FNAC cell blocks, remarkably reducing the @entity5 diagnostic category.

title: Immunohistochemical subtyping of @entity5 XXXX in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation.

answer: @entity6


abstract: BACKGROUND: Histopathological subtyping of @entity5 ( @entity5 ) is currently relevant in treatment decision because of a differential activity of specific therapeutic agents. Immunohistochemistry highlights cell differentiation lineages and, in this study, it was applied to maximize the proportion of accurately subtyped @entity5 @entity6 ( @entity6 ) on fine-needle aspiration cytology (FNAC) samples. METHODS: Cell blocks from 103 FNAC samples with a morphological diagnosis of @entity5 were immunostained for cytokeratin (CK) 7, @entity7 , @entity10 , and @entity8 , whereas @entity8 , napsin A (Naps-A), and @entity11 ( @entity11 ) were only assessed in a subgroup of cases with discordant ( @entity9 and @entity10 + for nonsquamous, @entity7 and @entity8 + for squamous) findings. Results were correlated with surgical specimens evaluated by morphology alone. RESULTS: Thirty-seven (36%) @entity1 with @entity9 / @entity10 + and @entity7 / @entity8 - corresponded to 35 cases of @entity3 ( @entity3 ) and 2 cases of @entity2 , whereas 9 (9%) cases with the reverse immunoprofile were @entity4 ( @entity4 ) at surgery (P < .001). Although the remaining 57 cases had different marker combinations, a correlation was found with @entity3 histology for @entity10 + samples (independent of other markers) and with @entity4 for @entity8 +/ @entity10 - immunophenotype (P < .001). @entity8 was never expressed in @entity8 + @entity3 , whereas Naps-A was restricted to @entity3 and @entity11 to @entity4 lineage. The percentage of unclassified @entity5 decreased from 36% to 14%. Combinations of 2 antibodies ( @entity10 / @entity11 or @entity8 /Naps-A) in the same section allowed diagnostic optimization in scant cytological samples. CONCLUSIONS: [corrected] This 4-antibody panel approach may contribute to refine @entity0 classification in FNAC cell blocks, remarkably reducing the @entity5 diagnostic category.

title: Immunohistochemical subtyping of XXXX @entity6 in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation.

answer: @entity5


abstract: The term " @entity11 " (VA) usually refers to a @entity5 ( @entity5 ). However, a group of @entity7 called VAs shows no @entity2 on angiography. The clinical and histological features of histologically classified VAs were studied in eight @entity0 who presented with @entity4 or @entity3 to reevaluate these @entity6 . Angiography showed no @entity2 in six @entity0 . Histological study included immunostaining for smooth muscle actin and glial fibrillary acidic protein. Surgical specimens of 10 cases of @entity8 , 10 cases of @entity9 , and two cases of @entity12 were studied to compare these types of VAs. Angiographically occult VAs were surgically removed safely, whereas removal of DVAs was complicated by @entity1 and @entity10 . Histological examination found angiographically occult VAs contained malformed and compactly arranged vessels with partly degenerated walls, whereas DVAs had dilated thin-walled vessels that were diffusely distributed in the normal white matter. This study of our cases and a review of the reported cases of VAs suggests that two different clinical and pathological entities are commonly categorized as "VA," angiographically occult VAs and DVAs. These two entities should be carefully distinguished.

title: Histologically classified XXXX of the brain: a controversy.

answer: @entity11


abstract: @entity5 events are a well-reported complication following the Fontan procedure, but no previous studies have compared the incidence of @entity5 events relative to the prophylactic anticoagulation strategy utilized. We examined the time-adjusted incidence of late @entity5 events relative to chronic anticoagulation strategy. All @entity0 who have undergone Fontan palliation and are followed at our institution were reviewed. All @entity5 and major @entity3 events were recorded and compared among different subgroups (anticoagulant medication utilized, Fontan variant, and the presence of a residual right-to-left shunt). The incidence of late @entity1 ( @entity1 ) per @entity0 -year was calculated for each subgroup. The records of 132 @entity0 were analyzed (median follow-up, 7.6 years; 1066.5 total @entity0 -years). There were no major @entity3 complications. One @entity0 receiving no anticoagulation therapy developed a symptomatic @entity4 6 months after Fontan. Three @entity0 suffered late @entity1 (range, 3-7 years); 2 were receiving @entity2 , and the other received no anticoagulation therapy. @entity6 had lateral tunnel Fontan and a residual right-to-left shunt. The overall incidence of late @entity1 was 2.3%, with an event rate of 0.28% per @entity0 -year. Late @entity1 was not related to anticoagulation strategy or time from Fontan procedure but was associated with a residual right-to-left shunt and lateral tunnel-type Fontan palliation (p < 0.001). Regardless of anticoagulation strategy utilized, symptomatic @entity1 is a rare long-term complication following the Fontan procedure.

title: Anticoagulation and incidence of late XXXX following the Fontan procedure.

answer: @entity1


abstract: PURPOSE: To determine if lymphatic channels and sentinel lymph nodes (SLNs) with and without @entity0 can be detected with lymphatic ultrasonography (US) after peritumoral injection of a US contrast agent and to determine if lymphatic US can be used to assess SLNs for the presence of metastatic infiltration. MATERIALS AND METHODS: Six @entity2 with 17 @entity1 were evaluated. Conventional gray-scale, color flow, and gray-scale phase-inversion harmonic US examinations were performed. A US contrast agent was administered in four sites around each @entity1 (1-mL total dose). Lymphoscintigraphy was followed by injection of a blue dye and then dissection. SLNs identified at lymphatic US were characterized by two readers in consensus as normal or as having @entity0 ; results were compared with histologic findings. Statistical analyses included the sign test and the kappa statistic. RESULTS: Lymphatic US depicted 28 SLNs, while lymphoscintigraphy depicted 27 "hot spots" suspected of representing SLNs (including two false-positive findings). Dissection after blue dye injection helped identify 31 SLNs. There were no false-positive US findings for @entity3 detection. Five of six nodes not seen with lymphoscintigraphy were detected with lymphatic US. The accuracy of @entity3 detection was 90% (28 of 31) for lymphatic US and 81% (25 of 31) for lymphoscintigraphy (P =.29). Lymphatic US correctly depicted @entity0 in 19 of 20 SLNs, and five of the eight normal SLNs were correctly characterized, with an accuracy of 86% (kappa = 0.62). CONCLUSION: Detection of SLNs with lymphatic US compared favorably with that at lymphoscintigraphy. Lymphatic US can depict @entity0 within the @entity3 , which was not possible with lymphoscintigraphy.

title: Sentinel lymph nodes in a @entity2 model with XXXX : contrast-enhanced lymphatic US.

answer: @entity1


abstract: PURPOSE: To determine if lymphatic channels and sentinel lymph nodes (SLNs) with and without @entity0 can be detected with lymphatic ultrasonography (US) after peritumoral injection of a US contrast agent and to determine if lymphatic US can be used to assess SLNs for the presence of metastatic infiltration. MATERIALS AND METHODS: Six @entity2 with 17 @entity1 were evaluated. Conventional gray-scale, color flow, and gray-scale phase-inversion harmonic US examinations were performed. A US contrast agent was administered in four sites around each @entity1 (1-mL total dose). Lymphoscintigraphy was followed by injection of a blue dye and then dissection. SLNs identified at lymphatic US were characterized by two readers in consensus as normal or as having @entity0 ; results were compared with histologic findings. Statistical analyses included the sign test and the kappa statistic. RESULTS: Lymphatic US depicted 28 SLNs, while lymphoscintigraphy depicted 27 "hot spots" suspected of representing SLNs (including two false-positive findings). Dissection after blue dye injection helped identify 31 SLNs. There were no false-positive US findings for @entity3 detection. Five of six nodes not seen with lymphoscintigraphy were detected with lymphatic US. The accuracy of @entity3 detection was 90% (28 of 31) for lymphatic US and 81% (25 of 31) for lymphoscintigraphy (P =.29). Lymphatic US correctly depicted @entity0 in 19 of 20 SLNs, and five of the eight normal SLNs were correctly characterized, with an accuracy of 86% (kappa = 0.62). CONCLUSION: Detection of SLNs with lymphatic US compared favorably with that at lymphoscintigraphy. Lymphatic US can depict @entity0 within the @entity3 , which was not possible with lymphoscintigraphy.

title: Sentinel lymph nodes in a XXXX model with @entity1 : contrast-enhanced lymphatic US.

answer: @entity2


abstract: A randomized comparison of @entity6 (2 g intravenously every eight hours) versus @entity3 (1.5 mg/kg intravenously every eight hours), each with @entity5 (600 mg intravenously every six hours), was performed in 119 @entity0 with @entity7 after cesarean section. @entity0 in both groups had similar risk factors. Genital cultures revealed an average of 3.0 isolates per specimen. Eighty-five aerobic gram-negative rods were isolated from 57 (48%) @entity0 . All were susceptible to both @entity6 and @entity3 . Of 133 anaerobic isolates, 131 (98%) were susceptible to @entity5 . The failures in the @entity6 group were associated with a wound abscess and with an @entity4 . Of the six failures in the @entity3 group, two were associated with persistent isolation of enteric bacilli. In the other four failures, no explanation was evident. Side effects occurred in four @entity0 , (three @entity2 , one @entity1 ). All were self-limited and appeared to be due to @entity5 . No @entity0 showed nephrotoxicity. When used in combination with @entity5 , @entity6 gave clinical results similar to @entity3 .

title: @entity6 versus XXXX , each with @entity5 , in the treatment of @entity7 .

answer: @entity3


abstract: A randomized comparison of @entity6 (2 g intravenously every eight hours) versus @entity3 (1.5 mg/kg intravenously every eight hours), each with @entity5 (600 mg intravenously every six hours), was performed in 119 @entity0 with @entity7 after cesarean section. @entity0 in both groups had similar risk factors. Genital cultures revealed an average of 3.0 isolates per specimen. Eighty-five aerobic gram-negative rods were isolated from 57 (48%) @entity0 . All were susceptible to both @entity6 and @entity3 . Of 133 anaerobic isolates, 131 (98%) were susceptible to @entity5 . The failures in the @entity6 group were associated with a wound abscess and with an @entity4 . Of the six failures in the @entity3 group, two were associated with persistent isolation of enteric bacilli. In the other four failures, no explanation was evident. Side effects occurred in four @entity0 , (three @entity2 , one @entity1 ). All were self-limited and appeared to be due to @entity5 . No @entity0 showed nephrotoxicity. When used in combination with @entity5 , @entity6 gave clinical results similar to @entity3 .

title: @entity6 versus @entity3 , each with XXXX , in the treatment of @entity7 .

answer: @entity5


abstract: A randomized comparison of @entity6 (2 g intravenously every eight hours) versus @entity3 (1.5 mg/kg intravenously every eight hours), each with @entity5 (600 mg intravenously every six hours), was performed in 119 @entity0 with @entity7 after cesarean section. @entity0 in both groups had similar risk factors. Genital cultures revealed an average of 3.0 isolates per specimen. Eighty-five aerobic gram-negative rods were isolated from 57 (48%) @entity0 . All were susceptible to both @entity6 and @entity3 . Of 133 anaerobic isolates, 131 (98%) were susceptible to @entity5 . The failures in the @entity6 group were associated with a wound abscess and with an @entity4 . Of the six failures in the @entity3 group, two were associated with persistent isolation of enteric bacilli. In the other four failures, no explanation was evident. Side effects occurred in four @entity0 , (three @entity2 , one @entity1 ). All were self-limited and appeared to be due to @entity5 . No @entity0 showed nephrotoxicity. When used in combination with @entity5 , @entity6 gave clinical results similar to @entity3 .

title: @entity6 versus @entity3 , each with @entity5 , in the treatment of XXXX .

answer: @entity7


abstract: A randomized comparison of @entity6 (2 g intravenously every eight hours) versus @entity3 (1.5 mg/kg intravenously every eight hours), each with @entity5 (600 mg intravenously every six hours), was performed in 119 @entity0 with @entity7 after cesarean section. @entity0 in both groups had similar risk factors. Genital cultures revealed an average of 3.0 isolates per specimen. Eighty-five aerobic gram-negative rods were isolated from 57 (48%) @entity0 . All were susceptible to both @entity6 and @entity3 . Of 133 anaerobic isolates, 131 (98%) were susceptible to @entity5 . The failures in the @entity6 group were associated with a wound abscess and with an @entity4 . Of the six failures in the @entity3 group, two were associated with persistent isolation of enteric bacilli. In the other four failures, no explanation was evident. Side effects occurred in four @entity0 , (three @entity2 , one @entity1 ). All were self-limited and appeared to be due to @entity5 . No @entity0 showed nephrotoxicity. When used in combination with @entity5 , @entity6 gave clinical results similar to @entity3 .

title: XXXX versus @entity3 , each with @entity5 , in the treatment of @entity7 .

answer: @entity6


abstract: BACKGROUND: Laser epithelial keratomileusis (LASEK) is a new keratorefractive procedure for the correction of @entity4 and @entity3 , which may combine advantages and eliminate disadvantages of photorefractive keratectomy (e.g. @entity1 , corneal haze) and laser in situ keratomileusis (e.g. flap and interface complications, @entity2 , keratectasia). We present the results of 108 consecutively LASEK-treated eyes with a follow-up period of 12 months. @entity0 AND METHODS: LASEK was performed on 108 consecutive eyes with @entity4 or @entity3 using a keracor 117 excimer laser. The mean preoperative refraction was -4.12+/-1.30 diopters (D) spherical equivalent range: -1.75 to -6.0 D and maximal cylinder was 3.25 D. Results of the 12 months visit are available for 101 eyes (93.5%). RESULTS: No serious complications were observed. After 12 months, SE was within +/-1.0 D of emmetropia in 96% and within +/-0.5 D in 86% of the eyes; 6 eyes had to be retreated. None of the eyes showed haze worse than grade 1 or lost more than one line of best-corrected visual acuity. Uncorrected visual acuity (UCVA) was > or =20/20 in 80% and > or =20/40 in 98%. CONCLUSIONS: Laser epithelial keratomileusis (LASEK) seems to be safe and effective in treatment of @entity4 and @entity3 of up to -6.0 D. Preliminary results compare favourably with those after photorefractive keratectomy and laser in situ keratomileusis. Haze formation after LASEK seems to be low. Coverage of the stromal wound with a vital epithelial flap could positively influence postoperative wound healing reactions.

title: [Laser epithelial keratomileusis (LASEK) for treatment of XXXX up to -6.0 D. Results from 108 eyes after 12 months].

answer: @entity4


abstract: INTRODUCTION: Recent data suggest a favorable prognosis for @entity1 @entity0 with a pathologic complete response to preoperative combined modality therapy. Prolongation of the interval between preoperative combined modality therapy and surgery (RT-surgery interval) as a means of increasing pathologic complete response rate has not been fully examined. METHODS: One hundred and fifty-five @entity1 @entity0 undergoing preoperative pelvic external beam radiation therapy and @entity3 -based chemotherapy followed by rectal resection were identified. All @entity0 had endorectal ultrasound prior to combined modality therapy. Final pathology reports were reviewed for ypT and ypN stage and margin status. Medical records were reviewed for sphincter preservation, operative time, estimated @entity2 , hospital stay, and morbidity (overall, anastomotic, and perineal). RESULTS: A pathologic complete response (ypT0N0) occurred in 24 @entity0 (15 percent). Median RT-surgery interval was 44 (range, 15-206) days. A pathologic complete response occurred in 19 percent of @entity0 with an interval >44 days, vs. 12 percent in those with an interval < or =44 days ( P = 0.27). Downstaging by three stages occurred more frequently in the long-interval group (15 percent vs. 6 percent, P = 0.11). The rates of sphincter preservation, positive margins, estimated @entity2 , and operative time were not significantly different. Overall morbidity was similar between groups. CONCLUSIONS: Our results demonstrate a trend toward increased pathologic complete response rate and downstaging with increased RT-surgery interval. However, sphincter preservation is not increased. Until prospective analyses are conducted assessing the impact of prolonged RT-surgery interval on long-term outcome, the benefit of a prolonged interval between the completion of preoperative combined modality therapy and surgery remains unclear.

title: Rate of pathologic complete response with increased interval between preoperative combined modality therapy and XXXX resection.

answer: @entity1


abstract: PURPOSE: The behavior of intra-abdominal desmoids in @entity2 is incompletely understood. Findings range from typical mass lesions to flat sheets, termed the desmoid reaction or desmoid precursor lesion. The latter often are incidental findings of uncertain significance. The study was designed to describe the natural history of @entity1 with particular reference to the desmoid reaction. METHODS: @entity0 who underwent laparotomy for @entity2 at the Cleveland Clinic Foundation were identified. The incidence of @entity1 was determined by review of operative records. @entity1 were classified as mass lesions if three-dimensional or desmoid reaction if two-dimensional. The incidence of clinically apparent @entity1 (typical mass lesions on physical examination or cross-sectional imaging in symptomatic @entity0 ) was determined by chart review. The incidence of clinical @entity1 between groups was compared by Fisher's exact test. RESULTS: A total of 266 @entity0 (153 females; median age, 26 (range, 9-63) years) underwent abdominal surgery for @entity2 . @entity1 were identified in 34 @entity0 : 8 at the index surgery and 26 at relaparotomy. These lesions influenced the planned procedure in eight cases (26 percent), including preventing ileoanal pouch in 3 of 19 @entity0 in whom this was intended. The median follow-up from the time of identification of intra-abdominal desmoids was 42 (range, 2-178) months at which point four @entity0 (11 percent) had developed clinical @entity1 . There was no significant difference in incidence of clinical @entity1 between mass and desmoid reaction groups ( P = 0.27). CONCLUSIONS: @entity1 are a common finding at relaparotomy in @entity0 with @entity2 . These lesions influence planned surgery in a minority of cases. Desmoid reaction may have little bearing on the subsequent development of clinically significant @entity1 .

title: Significance of incidental desmoids identified during surgery for XXXX .

answer: @entity2


abstract: A new single-antibiotic combination of @entity5 and @entity2 was compared with the standard two-drug regimen of @entity4 and @entity3 in the treatment of post-cesarean @entity6 . The regimens were as follows: 3 g of @entity5 plus 100 mg of @entity2 intravenously every four hours; or 600 mg of @entity4 intravenously every six hours plus 3 to 5 mg/kg per day of @entity3 intramuscularly. The prospective randomized schedule was calculated such that half the @entity0 were assigned to each treatment group. The diagnosis of @entity6 was based upon an elevated oral temperature of 100.4 degrees F or higher on any two occasions, excluding the first 24 hours after delivery, uterine tenderness, and the absence of other foci of @entity1 . Lochial discharge was foul in most cases. Forty-seven @entity0 were treated. Treatment was successful in all @entity0 who received @entity4 and @entity3 ; @entity5 plus @entity2 failed in two of 23 (9 percent) @entity0 . @entity0 in whom treatment failed did not appear to be different from those in whom treatment was successful on demographic variables or in terms of risk factors for @entity6 . The difference between the treatment failure rates was not statistically significant. This study suggests that the single-drug combination of @entity5 plus @entity2 is effective in the treatment of post-cesarean @entity6 when compared with the standard regimen of @entity4 and @entity3 .

title: Comparative clinical evaluation of @entity5 plus XXXX versus @entity4 plus @entity3 in treatment of post-cesarean @entity6 .

answer: @entity2


abstract: A new single-antibiotic combination of @entity5 and @entity2 was compared with the standard two-drug regimen of @entity4 and @entity3 in the treatment of post-cesarean @entity6 . The regimens were as follows: 3 g of @entity5 plus 100 mg of @entity2 intravenously every four hours; or 600 mg of @entity4 intravenously every six hours plus 3 to 5 mg/kg per day of @entity3 intramuscularly. The prospective randomized schedule was calculated such that half the @entity0 were assigned to each treatment group. The diagnosis of @entity6 was based upon an elevated oral temperature of 100.4 degrees F or higher on any two occasions, excluding the first 24 hours after delivery, uterine tenderness, and the absence of other foci of @entity1 . Lochial discharge was foul in most cases. Forty-seven @entity0 were treated. Treatment was successful in all @entity0 who received @entity4 and @entity3 ; @entity5 plus @entity2 failed in two of 23 (9 percent) @entity0 . @entity0 in whom treatment failed did not appear to be different from those in whom treatment was successful on demographic variables or in terms of risk factors for @entity6 . The difference between the treatment failure rates was not statistically significant. This study suggests that the single-drug combination of @entity5 plus @entity2 is effective in the treatment of post-cesarean @entity6 when compared with the standard regimen of @entity4 and @entity3 .

title: Comparative clinical evaluation of XXXX plus @entity2 versus @entity4 plus @entity3 in treatment of post-cesarean @entity6 .

answer: @entity5


abstract: A new single-antibiotic combination of @entity5 and @entity2 was compared with the standard two-drug regimen of @entity4 and @entity3 in the treatment of post-cesarean @entity6 . The regimens were as follows: 3 g of @entity5 plus 100 mg of @entity2 intravenously every four hours; or 600 mg of @entity4 intravenously every six hours plus 3 to 5 mg/kg per day of @entity3 intramuscularly. The prospective randomized schedule was calculated such that half the @entity0 were assigned to each treatment group. The diagnosis of @entity6 was based upon an elevated oral temperature of 100.4 degrees F or higher on any two occasions, excluding the first 24 hours after delivery, uterine tenderness, and the absence of other foci of @entity1 . Lochial discharge was foul in most cases. Forty-seven @entity0 were treated. Treatment was successful in all @entity0 who received @entity4 and @entity3 ; @entity5 plus @entity2 failed in two of 23 (9 percent) @entity0 . @entity0 in whom treatment failed did not appear to be different from those in whom treatment was successful on demographic variables or in terms of risk factors for @entity6 . The difference between the treatment failure rates was not statistically significant. This study suggests that the single-drug combination of @entity5 plus @entity2 is effective in the treatment of post-cesarean @entity6 when compared with the standard regimen of @entity4 and @entity3 .

title: Comparative clinical evaluation of @entity5 plus @entity2 versus XXXX plus @entity3 in treatment of post-cesarean @entity6 .

answer: @entity4


abstract: A new single-antibiotic combination of @entity5 and @entity2 was compared with the standard two-drug regimen of @entity4 and @entity3 in the treatment of post-cesarean @entity6 . The regimens were as follows: 3 g of @entity5 plus 100 mg of @entity2 intravenously every four hours; or 600 mg of @entity4 intravenously every six hours plus 3 to 5 mg/kg per day of @entity3 intramuscularly. The prospective randomized schedule was calculated such that half the @entity0 were assigned to each treatment group. The diagnosis of @entity6 was based upon an elevated oral temperature of 100.4 degrees F or higher on any two occasions, excluding the first 24 hours after delivery, uterine tenderness, and the absence of other foci of @entity1 . Lochial discharge was foul in most cases. Forty-seven @entity0 were treated. Treatment was successful in all @entity0 who received @entity4 and @entity3 ; @entity5 plus @entity2 failed in two of 23 (9 percent) @entity0 . @entity0 in whom treatment failed did not appear to be different from those in whom treatment was successful on demographic variables or in terms of risk factors for @entity6 . The difference between the treatment failure rates was not statistically significant. This study suggests that the single-drug combination of @entity5 plus @entity2 is effective in the treatment of post-cesarean @entity6 when compared with the standard regimen of @entity4 and @entity3 .

title: Comparative clinical evaluation of @entity5 plus @entity2 versus @entity4 plus @entity3 in treatment of post-cesarean XXXX .

answer: @entity6


abstract: A new single-antibiotic combination of @entity5 and @entity2 was compared with the standard two-drug regimen of @entity4 and @entity3 in the treatment of post-cesarean @entity6 . The regimens were as follows: 3 g of @entity5 plus 100 mg of @entity2 intravenously every four hours; or 600 mg of @entity4 intravenously every six hours plus 3 to 5 mg/kg per day of @entity3 intramuscularly. The prospective randomized schedule was calculated such that half the @entity0 were assigned to each treatment group. The diagnosis of @entity6 was based upon an elevated oral temperature of 100.4 degrees F or higher on any two occasions, excluding the first 24 hours after delivery, uterine tenderness, and the absence of other foci of @entity1 . Lochial discharge was foul in most cases. Forty-seven @entity0 were treated. Treatment was successful in all @entity0 who received @entity4 and @entity3 ; @entity5 plus @entity2 failed in two of 23 (9 percent) @entity0 . @entity0 in whom treatment failed did not appear to be different from those in whom treatment was successful on demographic variables or in terms of risk factors for @entity6 . The difference between the treatment failure rates was not statistically significant. This study suggests that the single-drug combination of @entity5 plus @entity2 is effective in the treatment of post-cesarean @entity6 when compared with the standard regimen of @entity4 and @entity3 .

title: Comparative clinical evaluation of @entity5 plus @entity2 versus @entity4 plus XXXX in treatment of post-cesarean @entity6 .

answer: @entity3


abstract: Viozan, (Sibenadet @entity5 , @entity7 ) is a dual D2 @entity1 receptor, @entity3 agonist that combines bronchodilator activity with the sensory afferent modulating effects associated with D2-receptor agonism. Investigation in animal models of key @entity2 ( @entity2 ) symptoms has demonstrated that sibenadet effectively inhibits sensory nerve activity, thereby reducing reflex cough, mucus production and tachypnoea. The results of the early clinical evaluation of this novel agent are reported. An initial proof of concept study (Study 1) aimed to determine the clinical potential of this novel agent by assessing the effects of three doses of sibenadet therapy relative to placebo, with two commonly used bronchodilators, intended to provide a benchmark against which sibenadet activity could be judged. In all, 701 @entity0 were randomized to one of three sibenadet dose groups (400, 600 or 1000 microg ex valve), @entity4 200 microg, @entity6 (IB) 40 microg or placebo, all three times daily via pressurized metered dose inhaler (pMDI) for 4 weeks. Once the results of Study 1 had been evaluated, a dose-ranging, study (Study 2) involving 872 @entity0 randomized to receive sibenadet (45, 270, or 495 microg ex actuator), or placebo all three times daily via pMDI, for 6 weeks commenced. Both studies were preceded by a 2-week baseline phase and followed by a 2-week follow up period.The primary efficacy variable identified changes in key @entity2 symptoms over the treatment period (compared with baseline data) as determined by the novel Breathlessness, Cough and Sputum Scale (BCSS). In addition, data on lung function, health-related quality of life and adverse events were collected. @entity0 receiving sibenadet therapy three times daily exhibited statistically significantly greater improvements in BCSS total score than those receiving placebo or bronchodilator therapy alone. A clear dose-response was evident in Study 2. Symptom improvement in this study was also accompanied by improved lung function and health-related quality of life. Sibenadet therapy was well tolerated with an adverse events profile comparable to current bronchodilator therapy. These data were viewed as extremely encouraging, warranting further, large-scale clinical investigation.

title: Early clinical investigation of Viozan (sibenadet @entity5 ), a novel D2 XXXX receptor, @entity3 agonist for the treatment of @entity2 .

answer: @entity1


abstract: Viozan, (Sibenadet @entity5 , @entity7 ) is a dual D2 @entity1 receptor, @entity3 agonist that combines bronchodilator activity with the sensory afferent modulating effects associated with D2-receptor agonism. Investigation in animal models of key @entity2 ( @entity2 ) symptoms has demonstrated that sibenadet effectively inhibits sensory nerve activity, thereby reducing reflex cough, mucus production and tachypnoea. The results of the early clinical evaluation of this novel agent are reported. An initial proof of concept study (Study 1) aimed to determine the clinical potential of this novel agent by assessing the effects of three doses of sibenadet therapy relative to placebo, with two commonly used bronchodilators, intended to provide a benchmark against which sibenadet activity could be judged. In all, 701 @entity0 were randomized to one of three sibenadet dose groups (400, 600 or 1000 microg ex valve), @entity4 200 microg, @entity6 (IB) 40 microg or placebo, all three times daily via pressurized metered dose inhaler (pMDI) for 4 weeks. Once the results of Study 1 had been evaluated, a dose-ranging, study (Study 2) involving 872 @entity0 randomized to receive sibenadet (45, 270, or 495 microg ex actuator), or placebo all three times daily via pMDI, for 6 weeks commenced. Both studies were preceded by a 2-week baseline phase and followed by a 2-week follow up period.The primary efficacy variable identified changes in key @entity2 symptoms over the treatment period (compared with baseline data) as determined by the novel Breathlessness, Cough and Sputum Scale (BCSS). In addition, data on lung function, health-related quality of life and adverse events were collected. @entity0 receiving sibenadet therapy three times daily exhibited statistically significantly greater improvements in BCSS total score than those receiving placebo or bronchodilator therapy alone. A clear dose-response was evident in Study 2. Symptom improvement in this study was also accompanied by improved lung function and health-related quality of life. Sibenadet therapy was well tolerated with an adverse events profile comparable to current bronchodilator therapy. These data were viewed as extremely encouraging, warranting further, large-scale clinical investigation.

title: Early clinical investigation of Viozan (sibenadet @entity5 ), a novel D2 @entity1 receptor, XXXX agonist for the treatment of @entity2 .

answer: @entity3


abstract: Viozan, (Sibenadet @entity5 , @entity7 ) is a dual D2 @entity1 receptor, @entity3 agonist that combines bronchodilator activity with the sensory afferent modulating effects associated with D2-receptor agonism. Investigation in animal models of key @entity2 ( @entity2 ) symptoms has demonstrated that sibenadet effectively inhibits sensory nerve activity, thereby reducing reflex cough, mucus production and tachypnoea. The results of the early clinical evaluation of this novel agent are reported. An initial proof of concept study (Study 1) aimed to determine the clinical potential of this novel agent by assessing the effects of three doses of sibenadet therapy relative to placebo, with two commonly used bronchodilators, intended to provide a benchmark against which sibenadet activity could be judged. In all, 701 @entity0 were randomized to one of three sibenadet dose groups (400, 600 or 1000 microg ex valve), @entity4 200 microg, @entity6 (IB) 40 microg or placebo, all three times daily via pressurized metered dose inhaler (pMDI) for 4 weeks. Once the results of Study 1 had been evaluated, a dose-ranging, study (Study 2) involving 872 @entity0 randomized to receive sibenadet (45, 270, or 495 microg ex actuator), or placebo all three times daily via pMDI, for 6 weeks commenced. Both studies were preceded by a 2-week baseline phase and followed by a 2-week follow up period.The primary efficacy variable identified changes in key @entity2 symptoms over the treatment period (compared with baseline data) as determined by the novel Breathlessness, Cough and Sputum Scale (BCSS). In addition, data on lung function, health-related quality of life and adverse events were collected. @entity0 receiving sibenadet therapy three times daily exhibited statistically significantly greater improvements in BCSS total score than those receiving placebo or bronchodilator therapy alone. A clear dose-response was evident in Study 2. Symptom improvement in this study was also accompanied by improved lung function and health-related quality of life. Sibenadet therapy was well tolerated with an adverse events profile comparable to current bronchodilator therapy. These data were viewed as extremely encouraging, warranting further, large-scale clinical investigation.

title: Early clinical investigation of Viozan (sibenadet @entity5 ), a novel D2 @entity1 receptor, @entity3 agonist for the treatment of XXXX .

answer: @entity2


abstract: Viozan, (Sibenadet @entity5 , @entity7 ) is a dual D2 @entity1 receptor, @entity3 agonist that combines bronchodilator activity with the sensory afferent modulating effects associated with D2-receptor agonism. Investigation in animal models of key @entity2 ( @entity2 ) symptoms has demonstrated that sibenadet effectively inhibits sensory nerve activity, thereby reducing reflex cough, mucus production and tachypnoea. The results of the early clinical evaluation of this novel agent are reported. An initial proof of concept study (Study 1) aimed to determine the clinical potential of this novel agent by assessing the effects of three doses of sibenadet therapy relative to placebo, with two commonly used bronchodilators, intended to provide a benchmark against which sibenadet activity could be judged. In all, 701 @entity0 were randomized to one of three sibenadet dose groups (400, 600 or 1000 microg ex valve), @entity4 200 microg, @entity6 (IB) 40 microg or placebo, all three times daily via pressurized metered dose inhaler (pMDI) for 4 weeks. Once the results of Study 1 had been evaluated, a dose-ranging, study (Study 2) involving 872 @entity0 randomized to receive sibenadet (45, 270, or 495 microg ex actuator), or placebo all three times daily via pMDI, for 6 weeks commenced. Both studies were preceded by a 2-week baseline phase and followed by a 2-week follow up period.The primary efficacy variable identified changes in key @entity2 symptoms over the treatment period (compared with baseline data) as determined by the novel Breathlessness, Cough and Sputum Scale (BCSS). In addition, data on lung function, health-related quality of life and adverse events were collected. @entity0 receiving sibenadet therapy three times daily exhibited statistically significantly greater improvements in BCSS total score than those receiving placebo or bronchodilator therapy alone. A clear dose-response was evident in Study 2. Symptom improvement in this study was also accompanied by improved lung function and health-related quality of life. Sibenadet therapy was well tolerated with an adverse events profile comparable to current bronchodilator therapy. These data were viewed as extremely encouraging, warranting further, large-scale clinical investigation.

title: Early clinical investigation of Viozan (sibenadet XXXX ), a novel D2 @entity1 receptor, @entity3 agonist for the treatment of @entity2 .

answer: @entity5


abstract: OBJECTIVES: To investigate T cell subsets and immune cytokine profiles in untreated @entity11 ( @entity11 ) @entity0 and the underlying immunopathological mechanism. METHODS: We enrolled 50 untreated @entity11 @entity0 and 40 age-matched controls (20 healthy controls, 20 untreated @entity6 @entity0 ). Enzyme-linked immunosorbent assays (ELISAs) were used to define cytokine profiles in all @entity0 , and flow cytometry was performed for 9 @entity11 @entity0 and 12 healthy controls. @entity7 and @entity8 (H _ E) staining and immunohistochemistry (IHC) were performed in aortic tissues of 9 @entity11 and 9 @entity4 @entity0 ; clinical data were also collected. RESULTS: Circulating CD4+ T cells were more frequent in @entity11 @entity0 (p<0.05). Frequencies of @entity5 , Th2, and Th17 cells were higher, whereas Treg cells were reduced in @entity11 . Significantly higher levels of @entity3 and lower levels of @entity1 , @entity9 , and @entity10 were detected in @entity11 @entity0 (p<0.05). By H _ E staining, thickened vascular walls with proliferation of collagen fibre were observed in most @entity0 . Inflammatory sites with infiltrating macrophages, lymphocytes, and neutrophils were located in adventitia. IHC revealed T cells (mainly CD4+ T cells) in @entity2 . Additionally, @entity3 was positive throughout the vascular wall in most specimens, whereas @entity1 , IL-12, and @entity10 were detected in inflammatory sites of active @entity0 . @entity3 levels were positively related to ESR, CRP, and Kerr scores (p<0.05). CONCLUSIONS: Significantly increased levels of @entity3 were detected in peripheral blood and aortic tissues of untreated @entity0 . @entity3 might be a sensitive biomarker to assess disease activity and could be critical in the immunopathogenesis of @entity11 .

title: The critical role of XXXX in the pathogenesis of @entity11 .

answer: @entity3


abstract: OBJECTIVES: To investigate T cell subsets and immune cytokine profiles in untreated @entity11 ( @entity11 ) @entity0 and the underlying immunopathological mechanism. METHODS: We enrolled 50 untreated @entity11 @entity0 and 40 age-matched controls (20 healthy controls, 20 untreated @entity6 @entity0 ). Enzyme-linked immunosorbent assays (ELISAs) were used to define cytokine profiles in all @entity0 , and flow cytometry was performed for 9 @entity11 @entity0 and 12 healthy controls. @entity7 and @entity8 (H _ E) staining and immunohistochemistry (IHC) were performed in aortic tissues of 9 @entity11 and 9 @entity4 @entity0 ; clinical data were also collected. RESULTS: Circulating CD4+ T cells were more frequent in @entity11 @entity0 (p<0.05). Frequencies of @entity5 , Th2, and Th17 cells were higher, whereas Treg cells were reduced in @entity11 . Significantly higher levels of @entity3 and lower levels of @entity1 , @entity9 , and @entity10 were detected in @entity11 @entity0 (p<0.05). By H _ E staining, thickened vascular walls with proliferation of collagen fibre were observed in most @entity0 . Inflammatory sites with infiltrating macrophages, lymphocytes, and neutrophils were located in adventitia. IHC revealed T cells (mainly CD4+ T cells) in @entity2 . Additionally, @entity3 was positive throughout the vascular wall in most specimens, whereas @entity1 , IL-12, and @entity10 were detected in inflammatory sites of active @entity0 . @entity3 levels were positively related to ESR, CRP, and Kerr scores (p<0.05). CONCLUSIONS: Significantly increased levels of @entity3 were detected in peripheral blood and aortic tissues of untreated @entity0 . @entity3 might be a sensitive biomarker to assess disease activity and could be critical in the immunopathogenesis of @entity11 .

title: The critical role of @entity3 in the pathogenesis of XXXX .

answer: @entity11


abstract: Modalities of @entity1 therapeutic follow-up are controversial, notably for biological and radiological parameters. We have proposed six weeks of antibiotic therapy for all @entity0 presenting with @entity1 , since July 2005. Therefore, biological and radiological exams performed during the treatment were not taken into account when determining the duration of antibiotherapy. This protocol allows determining the usefulness of these biological and radiological parameters. METHODS: All @entity0 presenting with @entity1 , from July 2005 to July 2008, were included. Inflammatory biological parameters such as C-reactive protein (CRP) and sedimentation rate were analyzed, and values were considered as normal when less than 10 mg/L and less than 15 mm respectively. All available CT- and MR imaging were analyzed by the same referent radiologist. RESULTS: Eighty-seven @entity0 presenting with @entity1 received antibiotic therapy for a mean [SD] 42    0.3 days. Cure was reported in 82 @entity0 (94%) with a mean follow-up after antibiotic therapy of 36    9 months, five @entity0 relapsed. CRP was available in 66 cases by the end of antibiotic therapy, it was normal in 40/64 of @entity0 with favorable outcome (62%) and in one case of unfavorable outcome. The sedimentation rate was available in 22 cases, and normal in seven cases of favorable outcome (32%). By the end of antibiotic therapy, CT-scan showed active @entity1 for 15/23 of @entity0 with favorable outcome (65%), while MR imaging suggested the same diagnosis in 8/14 cases (57%). CONCLUSION: Biological parameters and radiological findings are inadequate to determine the duration of antibiotic therapy in @entity1 .

title: [Duration of antibiotic therapy in XXXX and biological or radiological data].

answer: @entity1


abstract: BACKGROUND: @entity6 is an uncommon disorder resulting from @entity1 of the enterochromaffin cells. Current biochemical investigation usually involves the measurement of @entity3 ( @entity5 ) in 24-h urine collections. Because of the problems associated with urine collections (i.e. inconvenience, accuracy of collection and requirement for preservatives) two alternative markers, fasting plasma @entity5 and whole blood @entity2 ( @entity2 ), have been studied. METHODS AND RESULTS: Whole blood @entity2 concentration and plasma and urine @entity5 concentrations were measured by high-performance liquid chromatography in 31 @entity0 suspected of having @entity4 and 26 known @entity4 @entity0 . Receiver operator characteristic curve analysis of the data showed no statistical difference between the three markers (P>0.01) with regard to their discriminating function. However, fasting plasma @entity5 assay showed greater stability than whole blood @entity2 assay and is more convenient for the @entity0 than a 24-h urine collection. At a cut-off value of 118 nmol/L plasma @entity5 assay showed a sensitivity of 89%, a specificity of 97% and a test efficiency of 93%. Whole blood @entity2 assay was further limited by its saturation in platelets at 40 nmol/10(9) platelets which made it less suitable for monitoring the treatment of @entity6 . CONCLUSION: Fasting plasma @entity5 concentration provides a more convenient screening test for @entity4 and overcomes the problems associated with 24-h urine collections, without any loss of diagnostic precision.

title: Evaluation of whole blood @entity2 and plasma and urine XXXX in diagnosis of @entity6 .

answer: @entity3


abstract: BACKGROUND: @entity6 is an uncommon disorder resulting from @entity1 of the enterochromaffin cells. Current biochemical investigation usually involves the measurement of @entity3 ( @entity5 ) in 24-h urine collections. Because of the problems associated with urine collections (i.e. inconvenience, accuracy of collection and requirement for preservatives) two alternative markers, fasting plasma @entity5 and whole blood @entity2 ( @entity2 ), have been studied. METHODS AND RESULTS: Whole blood @entity2 concentration and plasma and urine @entity5 concentrations were measured by high-performance liquid chromatography in 31 @entity0 suspected of having @entity4 and 26 known @entity4 @entity0 . Receiver operator characteristic curve analysis of the data showed no statistical difference between the three markers (P>0.01) with regard to their discriminating function. However, fasting plasma @entity5 assay showed greater stability than whole blood @entity2 assay and is more convenient for the @entity0 than a 24-h urine collection. At a cut-off value of 118 nmol/L plasma @entity5 assay showed a sensitivity of 89%, a specificity of 97% and a test efficiency of 93%. Whole blood @entity2 assay was further limited by its saturation in platelets at 40 nmol/10(9) platelets which made it less suitable for monitoring the treatment of @entity6 . CONCLUSION: Fasting plasma @entity5 concentration provides a more convenient screening test for @entity4 and overcomes the problems associated with 24-h urine collections, without any loss of diagnostic precision.

title: Evaluation of whole blood XXXX and plasma and urine @entity3 in diagnosis of @entity6 .

answer: @entity2


abstract: BACKGROUND: @entity6 is an uncommon disorder resulting from @entity1 of the enterochromaffin cells. Current biochemical investigation usually involves the measurement of @entity3 ( @entity5 ) in 24-h urine collections. Because of the problems associated with urine collections (i.e. inconvenience, accuracy of collection and requirement for preservatives) two alternative markers, fasting plasma @entity5 and whole blood @entity2 ( @entity2 ), have been studied. METHODS AND RESULTS: Whole blood @entity2 concentration and plasma and urine @entity5 concentrations were measured by high-performance liquid chromatography in 31 @entity0 suspected of having @entity4 and 26 known @entity4 @entity0 . Receiver operator characteristic curve analysis of the data showed no statistical difference between the three markers (P>0.01) with regard to their discriminating function. However, fasting plasma @entity5 assay showed greater stability than whole blood @entity2 assay and is more convenient for the @entity0 than a 24-h urine collection. At a cut-off value of 118 nmol/L plasma @entity5 assay showed a sensitivity of 89%, a specificity of 97% and a test efficiency of 93%. Whole blood @entity2 assay was further limited by its saturation in platelets at 40 nmol/10(9) platelets which made it less suitable for monitoring the treatment of @entity6 . CONCLUSION: Fasting plasma @entity5 concentration provides a more convenient screening test for @entity4 and overcomes the problems associated with 24-h urine collections, without any loss of diagnostic precision.

title: Evaluation of whole blood @entity2 and plasma and urine @entity3 in diagnosis of XXXX .

answer: @entity6


abstract: For 25 years, 102 hematogenous @entity7 have been observed in 82 newborns and @entity0 . The hip joint was the most commun site of involvement (63 cases), than the knee (23 cases), the shoulder (7 cases), the elbow (5 cases), the ankle (3 cases) and one wrist. 14 times, two or more joints were involved. When the diagnosis was made early, an aspiration of pus and an irrigation of the joint was done. But in severe and delayed @entity3 , an arthrotomy was preferred. In all cases, joints were immobilized in a post-operative cast or with a traction management, and parenteral antibiotics were prescribed. 52 sequellae were noted, two third of these were seen in second hand. Sequellae are detailed joint by joint, and the authors describe different stages from minor @entity4 and abnormal growth of the epiphysis to severe destruction of the bones and persistent dislocation. Treatment of sequellae is proposed: 1. The hip joint. @entity4 and @entity1 were corrected with femoral osteotomy. In 2 cases, a pelvic innominate osteotomy was performed. Progressive @entity6 with short neck and greater trochanteric overgrowth were treated with femoral neck lengthening (personal technic). @entity5 needed open reduction of the hip and extensive excision of the acetabular fibro-fatty tissue. In a few cases, a Colonna's procedure was made. In total destructions of the upper femoral extremity, the treatment consisted in trochanteroplasty. In partial epiphysiodesis of a femoral condyle, disepiphysiodesis was obtained with resection of the physeal bone bridge (2 cases) or with free free physeal transplantation with microvascular @entity2 (2 cases).(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Osteoarthritis in XXXX . Follow-up and treatment].

answer: @entity0


abstract: OBJECTIVE: This study was designed to evaluate the long-term safety and effectiveness of repeated doses of the humanized anti-nerve growth factor antibody, tanezumab, during open-label treatment of @entity0 with @entity2 . DESIGN: The current study (clinicaltrials.gov identifier: NCT00399490) was a multicenter, phase II, open-label, multiple-dose extension of an earlier randomized clinical trial. All @entity0 (N=281) received infusions of tanezumab 50 g/kg on Days 1 and 56 with subsequent doses administered at 8-week intervals (up to a total of eight infusions). The primary endpoint of this study was safety. Effectiveness evaluations included overall knee @entity2 , Western Ontario and @entity3 (WOMAC) index subscales, and subject global assessment (SGA) of response to therapy on 0-100 point visual analog scales. RESULTS: Repeated administration of tanezumab resulted in a low incidence of treatment-related adverse events (AEs; 7.5%). The rate of serious AEs was also low (2.8%) with none considered treatment-related. Few @entity6 were reported; @entity5 was reported by nine @entity0 (3.2%), @entity4 by seven @entity0 (2.5%), and @entity7 , @entity6 , and @entity1 were each reported by one @entity0 (0.4% for each). Most @entity6 were rated as mild (95%) and the majority (65%) resolved before study completion. At Week 8, overall knee @entity2 and SGA improved from baseline by a mean (   standard error) of -12.8 (  1.78) and 8.0 (  1.66), respectively. Similar improvements occurred for WOMAC subscales. CONCLUSIONS: Repeated injections of tanezumab in @entity0 with moderate to severe knee @entity3 provide continued @entity2 relief and improved function with a low incidence of side effects. Additional studies to define the efficacy and duration of @entity2 reduction and to provide a more complete assessment of long-term safety are warranted.

title: Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee XXXX .

answer: @entity2


abstract: A consecutive series of 58 @entity0 , treated with the dynamic condylar screw (DCS) for subtrochanteric @entity1 were retrospectively reviewed. The mechanism of injury was low-energy in 47 cases and high-energy in 11 cases. Five @entity0 died before @entity1 healing. Ten out of 11 young @entity0 , (nine with high-energy injuries), united primarily. In contrast, the primary union rate in the elderly was 74%. Implant failure was seen in 11 cases (20%). Restricted weight bearing status post-operatively was associated with significantly lower incidence of implant failure (P<0.05, chi(2)-test). The use of bone graft was not related to @entity1 union (P>0.5). After revision surgery the overall union rate in the elderly was 90%. Using the DCS, the results were good in the young @entity0 with high-energy injuries. However, the implant failure rate is high in elderly @entity0 who suffer low-energy @entity1 . The DCS should not be used if weight bearing cannot be minimized in this group.

title: Results of dynamic condylar screw for subtrochanteric XXXX .

answer: @entity1


abstract: Between October 1995 and December 1998, 16 @entity0 with A-O type A3, C2 or C3 supracondylar femoral @entity1 were treated by open reduction and internal fixation using indirect reduction and bridge plating. Seven (44%) @entity0 had @entity5 . The @entity0 were followed for a mean of 46 months (range 24-71). All @entity1 healed. The average time for @entity1 @entity3 was 18.5 weeks (range 12-28). Four primary bone grafts and three secondary bone grafts were performed. By using the modified Schatzker rating scale, the result of 13 @entity0 (81%) were rated as excellent or good. Complications included two implant failures that were due to full weight bearing before bone @entity3 , and one superficial delayed wound @entity3 . No deep @entity2 were found in this series. The open @entity1 group needed longer time to heal and had a higher rate of receiving bone grafts. We conclude that indirect reduction and bridge plating with a 95 degrees dynamic condylar screw (DCS) or condylar blade plate can produce favourable results for @entity4 . We suggest primary bone grafts or early secondary bone grafts for @entity6 using an indirect reduction technique.

title: Indirect reduction and bridge plating of supracondylar XXXX of the femur.

answer: @entity1


abstract: BACKGROUND: The prognosis for @entity0 with most forms of @entity1 is poor. Allogeneic hematopoietic stem-cell transplantation (HSCT) may improve the outcome. @entity0 AND METHODS: This study examines the outcome of 52 @entity0 who underwent ablative or nonablative allogeneic HSCT for @entity4 ( @entity4 ) or @entity5 over a 12-year period at a single institution. We divided the @entity0 into those with predominantly nodal histologies: peripheral T-cell not otherwise specified ( @entity4 NOS), angioimmunoblastic (AITL), or @entity2 , T/null type (systemic) (ALCL), and predominantly extranodal histologies: natural killer (NK)/T cell, enteropathy type, hepatosplenic, subcutaneous @entity5 , or T cell or NK cell other. RESULTS: Median follow-up of survivors is 49 months. Non-relapse mortality and relapse at 3 years was 27% and 43%, respectively. The incidence of @entity3 ( @entity3 ) was 21%. The incidence of extensive chronic @entity3 at 2 years was 27%. The 3-year progression-free survival was 30%: 45% in @entity0 with predominantly nodal histologies ( @entity4 NOS, AITL, and ALCL) and 6% in @entity0 with predominantly extranodal histologies (P   =   0.016). Overall survival at 3 years was 41% for all @entity0 . CONCLUSION: Allogeneic HSCT can produce long-term remissions in relapsed/ @entity1 , especially those with nodal histologies.

title: A large single-center experience with allogeneic stem-cell transplantation for peripheral XXXX and @entity5 .

answer: @entity1


abstract: BACKGROUND: The prognosis for @entity0 with most forms of @entity1 is poor. Allogeneic hematopoietic stem-cell transplantation (HSCT) may improve the outcome. @entity0 AND METHODS: This study examines the outcome of 52 @entity0 who underwent ablative or nonablative allogeneic HSCT for @entity4 ( @entity4 ) or @entity5 over a 12-year period at a single institution. We divided the @entity0 into those with predominantly nodal histologies: peripheral T-cell not otherwise specified ( @entity4 NOS), angioimmunoblastic (AITL), or @entity2 , T/null type (systemic) (ALCL), and predominantly extranodal histologies: natural killer (NK)/T cell, enteropathy type, hepatosplenic, subcutaneous @entity5 , or T cell or NK cell other. RESULTS: Median follow-up of survivors is 49 months. Non-relapse mortality and relapse at 3 years was 27% and 43%, respectively. The incidence of @entity3 ( @entity3 ) was 21%. The incidence of extensive chronic @entity3 at 2 years was 27%. The 3-year progression-free survival was 30%: 45% in @entity0 with predominantly nodal histologies ( @entity4 NOS, AITL, and ALCL) and 6% in @entity0 with predominantly extranodal histologies (P   =   0.016). Overall survival at 3 years was 41% for all @entity0 . CONCLUSION: Allogeneic HSCT can produce long-term remissions in relapsed/ @entity1 , especially those with nodal histologies.

title: A large single-center experience with allogeneic stem-cell transplantation for peripheral @entity1 and XXXX .

answer: @entity5


abstract: OBJECTIVES: Several imaging modalities are commonly performed during work-up of @entity5 ( @entity5 ), but guidelines do not suggest any one technique. The aim of this study was to evaluate @entity1 and duct measurements by computed tomography (CT) and endoscopic ultrasound (EUS) and their ability to predict @entity4 ( @entity4 ) and @entity1 within @entity3 . METHODS: @entity0 with @entity5 who underwent preoperative CT and EUS between 2001 and 2009 were selected. Data were gathered retrospectively from medical records. RESULTS: The study group was comprised of 52 @entity0 , 33% (17/52) of whom had @entity4 or @entity1 . On fine needle aspirate (FNA), neither @entity2 ( @entity2 ) >200 nor cytological analysis correlated with @entity1 . In multivariate analysis, duct size >=  1.0 cm (P= 0.034) was a significant predictor of @entity4 or @entity1 , and diameter on CT scan (P= 0.056) approached significance. Lesion diameter of >=  2.5 cm on CT scan identified @entity1 in 71% (12/17) of @entity0 (P= 0.037). When analysed, all @entity0 with @entity4 or @entity1 had a lesion diameter >=  2.5 cm and/or a duct diameter >=  1.0 cm by CT scan. CONCLUSIONS: The use of radiographic criteria on CT including lesion size >=  2.5 cm and/or pancreatic duct diameter >=  1.0 cm appears to reliably identify @entity0 with either @entity4 or invasive @entity1 . High-resolution CT scanning may obviate the need for EUS and FNA in @entity0 with suspected @entity5 .

title: Endoscopic ultrasound may be unnecessary in the preoperative evaluation of XXXX .

answer: @entity5


abstract: RATIONALE: @entity0 studies and @entity1 models have provided evidence for @entity7 ( @entity7 )-based mechanisms as an underlying cause of @entity2 localized to the ascending aorta. In agreement with this associative evidence, we have published recently that @entity7 infusion induces aneurysmal pathology in the ascending aorta. OBJECTIVE: The aim of this study was to define the role of @entity7 type 1a ( @entity4 (1a)) receptors and their cellular location in @entity7 -induced ascending @entity3 ( @entity3 ). METHODS AND RESULTS: Male @entity5 (-/-) @entity1 were fed a saturated fat-enriched diet for 1 week before osmotic mini-pump implantation and infused with either saline or @entity7 (1000 ng/kg per minute) for 28 days. Intimal surface areas of ascending aortas were measured to quantify ascending @entity3 . Whole body @entity4 (1a) receptor deficiency ablated @entity7 -induced ascending @entity3 (P<0.001). To determine the role of @entity4 (1a) receptors on leukocytes, @entity5 (-/-) @entity4 (1a) receptor(+/+) or @entity4 (1a) receptor(-/-) @entity1 were irradiated and repopulated with bone marrow-derived cells isolated from either @entity4 (1a) receptor(+/+) or @entity4 (1a) receptor(-/-) @entity1 . @entity4 (1a) receptors in bone marrow-derived cells had no effect on @entity7 -induced ascending @entity3 . To determine the role of @entity4 (1a) receptors on vascular wall cells, we developed @entity4 (1a) receptor floxed @entity1 with depletion on either smooth muscle or endothelial cells using Cre driven by either @entity8 or @entity6 , respectively. @entity4 (1a) receptor deletion in smooth muscle cells had no effect on ascending @entity3 . In contrast, endothelial-specific depletion attenuated this pathology. CONCLUSIONS: @entity7 infusion promotes @entity2 in the ascending aorta via stimulation of @entity4 (1a) receptors that are expressed on endothelial cells.

title: Endothelial cell-specific deficiency of @entity7 type 1a receptors attenuates XXXX -induced ascending @entity3 in @entity5 -/- @entity1 .

answer: @entity7


abstract: RATIONALE: @entity0 studies and @entity1 models have provided evidence for @entity7 ( @entity7 )-based mechanisms as an underlying cause of @entity2 localized to the ascending aorta. In agreement with this associative evidence, we have published recently that @entity7 infusion induces aneurysmal pathology in the ascending aorta. OBJECTIVE: The aim of this study was to define the role of @entity7 type 1a ( @entity4 (1a)) receptors and their cellular location in @entity7 -induced ascending @entity3 ( @entity3 ). METHODS AND RESULTS: Male @entity5 (-/-) @entity1 were fed a saturated fat-enriched diet for 1 week before osmotic mini-pump implantation and infused with either saline or @entity7 (1000 ng/kg per minute) for 28 days. Intimal surface areas of ascending aortas were measured to quantify ascending @entity3 . Whole body @entity4 (1a) receptor deficiency ablated @entity7 -induced ascending @entity3 (P<0.001). To determine the role of @entity4 (1a) receptors on leukocytes, @entity5 (-/-) @entity4 (1a) receptor(+/+) or @entity4 (1a) receptor(-/-) @entity1 were irradiated and repopulated with bone marrow-derived cells isolated from either @entity4 (1a) receptor(+/+) or @entity4 (1a) receptor(-/-) @entity1 . @entity4 (1a) receptors in bone marrow-derived cells had no effect on @entity7 -induced ascending @entity3 . To determine the role of @entity4 (1a) receptors on vascular wall cells, we developed @entity4 (1a) receptor floxed @entity1 with depletion on either smooth muscle or endothelial cells using Cre driven by either @entity8 or @entity6 , respectively. @entity4 (1a) receptor deletion in smooth muscle cells had no effect on ascending @entity3 . In contrast, endothelial-specific depletion attenuated this pathology. CONCLUSIONS: @entity7 infusion promotes @entity2 in the ascending aorta via stimulation of @entity4 (1a) receptors that are expressed on endothelial cells.

title: Endothelial cell-specific deficiency of XXXX type 1a receptors attenuates @entity7 -induced ascending @entity3 in @entity5 -/- @entity1 .

answer: @entity7